|
Read on web → |
Colorado's cannabis licensees got two signals this week about how seriously the state treats product safety, and they point in opposite directions. A Denver lab flagged methylene chloride — an EPA-target carcinogen solvent — in StayCon LLC's Craft-brand vape cartridges roughly six weeks before the company issued a voluntary recall on September 18 and 19. The state's own consumer-facing Health and Safety Advisory did not follow until September 25, the same day ProPublica and the Denver Gazette published a joint investigation finding that Colorado's Marijuana Enforcement Division averages more than seven months to warn consumers about contaminated products after first receiving complaints. The recall covers 49 vape products, including the Maui Wowie and Grape Gorilla lines, sold at 405 dispensaries statewide. Three days after the advisory, on September 28, Colorado's expanded 30-solvent testing panel takes effect — a rule adopted well before this recall, and one that does nothing to fix the warning-delay problem the investigation documented. Elsewhere this week: Nevada finalized a sweeping delivery-and-testing overhaul, Missouri's Supreme Court heard argument on 13 contested cannabis licenses, and Thailand's Cabinet approved a draft law that would reverse the country's legal cannabis market back to medical-only use.
This week at a glanceTop story. A ProPublica/Denver Gazette investigation documents Colorado MED's pattern of multi-month delays warning consumers about contaminated cannabis products, published the same day the state finally advisoried a 405-store vape recall — three days before a new 30-solvent testing rule takes effect that fixes a different problem than the one the reporting found.
Next three.
- Nevada finalized a regulation package raising delivery capacity 2.5x and doubling minimum lab sample sizes, effective upon filing with the Secretary of State.
- Missouri's Supreme Court heard argument on whether 13 marijuana licenses tainted by inconsistent scoring should issue — no ruling, no date set.
- Thailand's Cabinet approved a draft law reversing the country's 2022 decriminalization back to medical-only use — a House vote is required, none scheduled.
We are opening a set of promotional placements across both The Regulator Brief and cannabisregulations.ai — an array of options built to span every budget, from single-issue newsletter placements to site-wide visibility on the state legality database and blog. Slots are limited, and for now they are offered only to newsletter subscribers and early users.
Fill out the form to learn more → Federal & agency deskWhy it matters: The exact process now deciding marijuana's federal schedule has no written procedural rulebook, per a congressional watchdog — a data point for anyone litigating or lobbying the rescheduling docket.
GAO-26-108623, published September 23, found DEA has no written policy on roles, responsibilities and procedures for evaluating and scheduling controlled substances, and that FDA similarly lacks documented scheduling-evaluation procedures. The report does not name marijuana specifically — it is a general audit published while DEA's Schedule III review remains open.
Why it matters: HHC already loses federal hemp status under the November 12 statutory cliff regardless of this case, but a ruling against DEA's separate Schedule I listing would matter for HHC's status in the interim and in states that haven't independently banned it.
A hemp company is petitioning the Fourth Circuit to review DEA's May 2026 rule specifically listing hexahydrocannabinol as Schedule I. At September 18 oral argument, Circuit Judges Albert Diaz and Toby Heytens reportedly appeared skeptical of DEA's rationale. No ruling has issued; talk to your counsel before relying on any predicted outcome.
Why it matters: Trade-association endorsement is a lobbying signal, not a legal change — but it's the clearest sign yet that the insurance side of the industry, not just operators, wants a federal safe harbor to move.
The American Property Casualty Insurance Association and the National Association of Mutual Insurance Companies formally endorsed the CLAIM Act (H.R. 10471 / S. 5049), which would create a federal safe harbor for insurers covering state-licensed cannabis businesses.
Why it matters: Colorado licensees holding StayCon/Craft-tagged vape inventory carry an immediate pull obligation, and the state's reliance on self-selected labs — rather than the independent sampling roughly 26 of 42 legal states require — is now a documented policy gap, not a hypothetical one.
A Denver lab detected methylene chloride in StayCon LLC's Craft-brand cartridges roughly six weeks before the company's September 18-19 recall. Colorado's Marijuana Enforcement Division posted its own consumer advisory September 25 — the day ProPublica and the Denver Gazette published findings that MED averages 7+ months to warn consumers after first complaints, citing a case with a 15-month gap during which a patient developed cirrhosis. MED disputed the broader characterization without rebutting the specific timeline. Separately, MED's expanded 30-solvent testing panel (up from 13) takes effect September 28.
Why it matters: Delivery fleets gain 2.5x per-trip capacity; testing labs face a real cost increase from the doubled minimum sample size — budget for it before the filing date, not after, since "upon filing" is not a calendar date.
The Nevada Legislative Commission gave final approval September 24 to LCB File No. R152-24. Single-delivery-trip capacity rises from 5 to 12.5 ounces; the minimum lab sample size for potency and contaminant testing rises from 10 to 20 grams; core under-21 advertising and child-resistant packaging rules are retained unchanged. Effective upon filing with the Secretary of State — no specific date confirmed.
Why it matters: A ruling for the challenger would put 13 new licenses into a market that already allocated its caps years ago — direct competitive exposure for every existing Missouri licensee, and a national precedent on outsourced scoring.
The state asked the Missouri Supreme Court on September 23 to reverse an appellate ruling that found the Administrative Hearing Commission's license-rescoring approach "completely flawed." Hippos LLC, which surfaced inconsistent scoring across its 2019 applications, asked the court to order the licenses issued outright. The seven justices did not rule from the bench — no date has been set.
Why it matters: No compliance impact for licensees, but a signal worth tracking for any medical program watching patient-access expansion into hospital settings.
House Bill 33, which would let terminally ill patients continue medical cannabis use while admitted to a health care facility, previously passed the House and is now before a Senate committee, which has scheduled a vote for September 29.
Why it matters: METRC and surveillance non-compliance remains Michigan's highest-frequency enforcement trigger — the same theme behind the $2 million Michigan Investment 10 fine two weeks ago.
The Cannabis Regulatory Agency's September 25 monthly report logged two non-renewals (T-Rex 1 Corp., DNVK Lapeer) and disciplinary actions against five licensees, including two Detroit-area operators, for METRC non-compliance and surveillance-camera gaps.
Why it matters: This would be the most significant reversal of any major legal cannabis market in 2026 if enacted — a live wind-down-planning trigger for any foreign operator with Thailand exposure, though it is not yet law.
Thailand's Cabinet approved a draft Cannabis Control Act on September 22 that would reinstate medical-use-only status, require dispensaries to convert to licensed medical facilities, and mandate farm registration by size tier. The bill now needs a House of Representatives vote — none scheduled.
Why it matters: A genuine compliance-burden reduction for Canadian federal licence holders — an estimated 378 hours saved annually each — though the implementation date is 2028, not immediate.
A September 26 Canada Gazette proposal would eliminate book-value and site-capacity reporting and remove tracking-order reporting entirely for provincial/territorial bodies and authorized retailers. Comments are due November 10; federal-licence-holder changes take effect January 1, 2028.
Advertising is now open. Placements across both the newsletter and the website, with promotional options for every budget. Slots are limited — offered to newsletter subscribers and early users first. Fill out the form →
Recreational, medical, THCA, Delta-8, Delta-9, HHC, CBD, and more — cross-referenced across all 50 states plus DC and Puerto Rico. Updated as laws move. The only single source operators can use to scope multi-state compliance before drafting product, packaging, or shipping policy.
Open the state laws database → Need help with anything in this brief?Get a plain-English answer sourced to primary law, in seconds.
Open the assistant →This newsletter is not legal advice — talk to your counsel. Our directory can help you find one.
Browse the directory → One thing to readThe D.C. Circuit's stay denial in the Schedule III merits challenge came up again this week in our reporting on the rescheduling docket's procedural posture — if you want the fuller mechanics of that ruling and what the case's briefing schedule is expected to look like, our own breakdown holds up well. Read the summary →
How useful was this week's brief?
In partnership with
Stop losing deals in between meetings.
Aligned is changing how B2B teams run their most important deals.
Most reps guess where a deal really stands. They forecast on a gut feeling and the buyer’s word vs what's actually happening. Then they realize the deal slipped through only after it's too late. Aligned surfaces what buyers are actually doing inside every deal: the risks, the openings, and the exact next step to keep things moving.
Start increasing your close rates and stand up your first deal room in minutes.
Reach the people who write the compliance checks.
The Regulator Brief goes out every Monday to cannabis attorneys, compliance officers, and licensed operators across US states and international jurisdictions. If you want to put your product in front of them, get in touch.
Know someone who'd benefit from this?
Forward it, or use your personal link below. Refer three colleagues and we'll send you our 50-state cannabis legality reference PDF.